NCT02652468 2022-01-05
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
University of Wisconsin, Madison
Phase NA Completed
Clinical Trials
10 trialsNCT01702961 2018-12-19
Rituxan+BEAM
Baylor College of Medicine
Phase NA Completed
NCT00772668 2017-12-11
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
University of Miami
Phase NA Terminated
NCT00594815 2017-04-06
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00648037 2016-02-01
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01230788 2014-12-01
Rituximab
Emory University
Phase NA Terminated
NCT00387023 2013-11-18
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
M.D. Anderson Cancer Center
Phase NA Completed
NCT00651755 2013-07-02
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
M.D. Anderson Cancer Center
Phase NA Completed
NCT00476229 2012-08-07
Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies
M.D. Anderson Cancer Center
Phase NA Completed
NCT00525876 2011-12-07
Non-Myeloablative Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase NA Completed